AMS (American Medical Systems) prices convertible debt offering:
This article was originally published in Clinica
American Medical Systems (AMS) last week priced $325m worth of convertible senior subordinated notes that will mature in 2036. The notes will be convertible either into cash or AMS shares, depending on the circumstances, said the Minneapolis, Minnesota company. The firm plans to use the net proceeds from the offering to fund part of its proposed $715m purchase of San Jose, California-based Laserscope (see Clinica No 1209, p 16), as well as for general working capital purposes. Should the Laserscope transaction fall through, AMS said it would use the proceeds for other possible acquisitions.
You may also be interested in...
Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.
The US FDA’s decision to ask on device adverse event reports whether the device involved had been serviced by a third party could help the agency as well as device makers, says Ricki Chase, compliance practice director at Lachman Consultant Services.